Region:North America
Author(s):Geetanshi
Product Code:KRAC9483
Pages:83
Published On:November 2025
By Type:The market is segmented into various diagnostic types, including Endoscopic Biopsy, Imaging Techniques, Blood-Based Biomarker Tests, Molecular Diagnostics, Liquid Biopsy, and Others. Among these, Endoscopic Biopsy remains the leading sub-segment due to its effectiveness in obtaining tissue samples for accurate diagnosis and guiding treatment decisions. Imaging Techniques, such as CT, MRI, ultrasound, and PET, are widely used for staging and monitoring disease progression. The adoption of advanced technologies—including AI-assisted imaging, digital pathology, and next-generation sequencing—is accelerating, with blood-based biomarker tests and liquid biopsy gaining traction for non-invasive early detection and monitoring.
By End-User:The market is categorized based on end-users, including Hospitals, Diagnostic Laboratories, Research Institutions, Outpatient Clinics, Academic Medical Centers, and Others. Hospitals are the dominant end-user segment, equipped with advanced diagnostic facilities and handling a higher patient inflow for comprehensive cancer care. The increasing number of cancer cases and the need for integrated diagnostic and treatment services drive this segment's growth. Diagnostic Laboratories play a crucial role in providing specialized testing services, particularly high-throughput molecular diagnostics and biomarker analysis, contributing significantly to overall market expansion. Research Institutions and Academic Medical Centers are pivotal in clinical trials, translational research, and the development of innovative diagnostic technologies.
The US Gastric Cancer Diagnostics Market is characterized by a dynamic mix of regional and international players. Leading participants such as Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic, Inc., Agilent Technologies, Illumina, Inc., Guardant Health, Inc., Exact Sciences Corporation, Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Becton, Dickinson and Company, Natera, Inc., QIAGEN N.V., Freenome Holdings, Inc., Paige.AI, Inc. contribute to innovation, geographic expansion, and service delivery in this space.
The future of the US gastric cancer diagnostics market is poised for significant transformation, driven by technological advancements and a shift towards preventive healthcare. As the integration of artificial intelligence in diagnostics becomes more prevalent, accuracy and efficiency in detecting gastric cancer will improve. Additionally, the expansion of telemedicine services is expected to enhance access to diagnostic consultations, particularly in rural areas. These trends will likely foster a more patient-centric approach, ultimately improving outcomes and market dynamics.
| Segment | Sub-Segments |
|---|---|
| By Type | Endoscopic Biopsy Imaging Techniques (CT, MRI, Ultrasound, PET) Blood-Based Biomarker Tests (e.g., CEA, CA 19-9, Pepsinogen) Molecular Diagnostics (NGS, PCR, FISH) Liquid Biopsy Others (e.g., Breath Tests, Stool Tests) |
| By End-User | Hospitals Diagnostic Laboratories Research Institutions Outpatient Clinics Academic Medical Centers Others |
| By Stage of Cancer | Early Stage (Stage I-II) Advanced Stage (Stage III-IV) Recurrence/Relapse Others (e.g., Precancerous Lesions) |
| By Technology | Immunohistochemistry (IHC) Next-Generation Sequencing (NGS) PCR-based Techniques Digital Pathology & AI-based Analysis Others |
| By Distribution Channel | Direct Sales Online Sales Distributors Others |
| By Geography | Northeast Midwest South West |
| By Patient Demographics | Age Group Gender Socioeconomic Status Ethnicity Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Oncologist Insights | 45 | Medical Oncologists, Surgical Oncologists |
| Diagnostic Laboratory Perspectives | 38 | Laboratory Managers, Pathologists |
| Patient Experience Feedback | 42 | Gastric Cancer Patients, Caregivers |
| Healthcare Provider Insights | 40 | Gastroenterologists, Primary Care Physicians |
| Medical Device Manufacturer Input | 35 | Product Managers, R&D Directors |
The US Gastric Cancer Diagnostics Market is valued at approximately USD 520 million, reflecting a significant growth driven by the rising prevalence of gastric cancer and advancements in diagnostic technologies.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.